Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 7/20 | 0.37 |
| ▸ | PPARG | P37231 | 6/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124569 | 0.82 | LMNA (0.51) | ALDH1A1SMN1; SMN2POLBHSD17B10HPGD | |
| SCHEMBL504044 | 0.79 | PPARG (0.54) | MAPTPPARAPPARGLMNAKDM4E | |
| SCHEMBL4885359 | 0.77 | PPARA (0.52) | SMN1; SMN2MAPTPPARAPPARGLMNA | |
| SCHEMBL5112891 | 0.77 | PPARG (0.46) | ALDH1A1POLBPPARAPPARGCA12 | |
| SCHEMBL4894747 | 0.77 | PPARG (0.51) | ALDH1A1SMN1; SMN2POLBHSD17B10HPGD | |
| SCHEMBL5109512 | 0.76 | ELANE (0.39) | ALDH1A1SMN1; SMN2POLBHSD17B10HPGD | |
| SCHEMBL4891207 | 0.75 | NPC1 (0.41) | SMN1; SMN2HPGDMAPTPPARAPPARG | |
| SCHEMBL6807064 | 0.75 | PPARA (0.45) | MAPTPPARAPPARGLMNATSHR | |
| SCHEMBL4898554 | 0.75 | MAPT (0.50) | ALDH1A1SMN1; SMN2POLBHSD17B10HPGD | |
| SCHEMBL4893815 | 0.74 | PPARA (0.50) | ALDH1A1SMN1; SMN2POLBMAPTPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1313716-B1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1313716-B1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20050245584-A1 | Peroxisome proliferator activated receptor agonists | BROOKS DAWN A | 2005-11-03 | — | — | US | disclosed |
| US-6930120-B2 | Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists | ELI LILLY AND COMPANY (US) | 2005-08-16 | — | — | US | disclosed |
| US-20040097590-A1 | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists | BROOKS DAWN ALISA (US) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097590-A1 | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists | PPARA, PPARG, PPARD | ALDH1A1 470/4885SMN1; SMN2 4686/4885POLB 1734/4885 |
| US-20050245584-A1 | Peroxisome proliferator activated receptor agonists | PPARG, PPARA, PPARD | ALDH1A1 1612/4885SMN1; SMN2 4858/4885POLB 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.